Key Points
- Guardant Health insider Terilyn Monroe sold 46,300 shares at an average price of $165.12, generating $7.65 million. The sale reduced Monroe’s holdings by 66.83% to 22,979 shares.
- GH shares opened at $159.54 and were down 3.4%, while trading near the upper end of their 52-week range of $53.40 to $176.58. Institutional investors own 92.6% of the company.
- Analysts remain broadly positive, with 23 Buy ratings and one Strong Buy versus one Sell rating. The consensus rating is “Moderate Buy,” with an average price target of $183.78.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) insider Terilyn Monroe sold 46,300 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the transaction, the insider owned 22,979 shares in the company, valued at approximately $3,794,292.48. This trade represents a 66.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Guardant Health Trading Down 3.4%
GH stock opened at $159.54 on Friday. Guardant Health, Inc. has a 1 year low of $53.40 and a 1 year high of $176.58. The company has a fifty day simple moving average of $149.77 and a 200 day simple moving average of $116.59. The firm has a market cap of $21.41 billion, a PE ratio of -45.71 and a beta of 1.60.
Hedge Funds Weigh In On Guardant Health
Institutional investors and hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC raised its stake in Guardant Health by 56.5% during the 1st quarter. AQR Capital Management LLC now owns 71,534 shares of the company's stock valued at $3,012,000 after purchasing an additional 25,831 shares during the last quarter. Empowered Funds LLC acquired a new stake in Guardant Health in the 1st quarter worth $274,000. Sei Investments Co. grew its position in Guardant Health by 15.8% in the 2nd quarter. Sei Investments Co. now owns 77,308 shares of the company's stock worth $4,023,000 after purchasing an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Guardant Health by 9.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company's stock worth $32,922,000 after purchasing an additional 54,284 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Guardant Health by 56.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company's stock worth $5,800,000 after purchasing an additional 40,209 shares during the period. Institutional investors own 92.60% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on GH. BTIG Research boosted their price target on Guardant Health from $190.00 to $195.00 and gave the stock a "buy" rating in a research report on Friday, July 31st. TD Cowen upped their price target on Guardant Health from $200.00 to $210.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Canaccord Genuity Group increased their price objective on Guardant Health from $135.00 to $205.00 and gave the company a "buy" rating in a report on Tuesday, July 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of Guardant Health in a research note on Friday, July 17th. Finally, Citigroup boosted their target price on Guardant Health from $150.00 to $215.00 and gave the stock a "buy" rating in a report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $183.78.
View Our Latest Research Report on GH
About Guardant Health
(
Get Free Report)
Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health's mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.
The company's flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
